Eli Lilly and Co. (NYSE: LLY) has detailed plans to pump $850 million into its U.S. operations this year. That includes a new $85 million expansion of the company’s Trulicity device assembly operations. The drugmaker says the investment is being driven by strong demand and its growing pipeline of potential cancer, pain and diabetes treatments. 

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}